Table of Contents :
• Stock Rating & Target Price
• Investment Thesis
• Fundamental Models Used
• Company Description
• Corporate Timeline
• Key Metrics (KPI ) and Recently Reported Earnings Review
• Business Highlights, Strategic Announcements & Outlook
• Quarter-over-Quarter (Q-o-Q) and Year-over-Year (Y-o-Y) Growth Analysis
• Key Catalysts Driving Growth
• Historical Financial Statement Analysis & CAGR Trends
• Quarterly Key Financial Ratios and Performance Metrics
• Annual Financial Performance Analysis: Horizontal and Vertical Financial Analysis, Trends
• Financial Forecasts
• Annual Forecasts: Income Statement
• Annual Forecasts: Cash Flow Statements
• Net Debt Levels
• A Closer Look at DCF: Our Assumptions and Methodology
• Terminal Value Calculation
• Target Price Analysis
• Valuation Multiples
• Supplementary Valuation Analysis: Multiples Approach
• Scenario/Sensitivity Analysis – Base Case , Bull Case ,Bear Case
• Holistic Peer Review & Trading Comps: Financial Data, Operational Metrics, and Valuation Multiples
• Implied Price Per Share
• Ownership Activity/ Insider Trades
• Ownership Summary
• An analysis of ESG Risk Rating
• Key Professionals
• Key Board Members
• Key Risks Considerations
• Analyst Ratings
• Analyst Industry Views
• Disclosures
Edwards Lifesciences (EW): Growth Is Back But Is Competitive Pressure About to Derail the Story?
Edwards Lifesciences enters 2026 with strong execution, reinforcing a durable growth algorithm anchored in its structural heart portfolio. Revenue grew 12.7% to $1.65B, with adjusted EPS outperforming expectations and operating margins expanding to over 31%, reflecting operating leverage and disciplined investment. TAVR remains the core earnings engine, delivering double-digit growth driven by procedural expansion and supported by long-term durability data and evolving treatment paradigms, while maintaining stable pricing. The TMTT segment is emerging as a high-growth driver, with over 40% revenue growth and expanding adoption across mitral and tricuspid therapies, supported by strong clinical data and ongoing product innovation. Surgical continues to provide steady growth, complemented by pipeline advancements. While growth is broad-based, execution risk remains as the company scales newer platforms and navigates competitive dynamics, particularly in TAVR and transcatheter therapies. Margins remain resilient despite ongoing investment in innovation and manufacturing capacity, and guidance implies continued double-digit earnings growth. With strong clinical catalysts and expanding market opportunities, the long-term outlook remains constructive. Can Edwards sustain its leadership in TAVR while successfully scaling TMTT and defending share against increasing competitive intensity?
